跳至主要内容
临床试验/CTRI/2010/091/000169
CTRI/2010/091/000169已完成3 期

A Phase III, Multicenter, Open Label, Randomized, Single Treatment study to evaluate the efficacy and safety of alpha,beta - arteether injection 150 mg/mL in patient of P. falciparum malaria.

incoln Pharmaceuticals Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Written informed consent from the patient.
  • 2.Male and Female patients with aged 18 years above inclusive.
  • 3. Diagnosis of Patients with P. falciparum malaria by the presence of ring forms of P. falciparum in thick and thin peripheral blood smears (parasitemia > 5%).

排除标准

  • 1. Patients with any condition which in the opinion of the investigator makes the patient unsuitable for inclusion.
  • 2. Patient is a female who is pregnant or willing to get pregnant, not ready to use contraceptive measures during the trial period or breast feeding.
  • 3. Known hypersensitivity to alpha,beta-arteether.
  • 4. Patient with renal failure and other systemic disorder.
  • 5. Patient who is consuming/ has received drugs, which have interaction with alpha,beta-arteether, during last 14 days.
  • 6. Participation in any other clinical trial during last 30 days.

研究者

发起方
incoln Pharmaceuticals Ltd

相似试验